In an effort to give you the best possible service, we would be grateful if you could take a few minutes of your time to answer a few questions.
My Saved Results
Join Our Mailing List
Home / Clinical Trials / Find Clinical Trials / A Multicenter, Single-Arm Open-Label Expanded Access Program for...
I'm a new user and need a user account
Forgot your password?
Subjects who qualify for participation will receive lenalidomide plus high dose dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for multiple myeloma.